Scott, Nick
Wilson, David P.
Thompson, Alexander J.
Barnes, Eleanor
El-Sayed, Manal
Benzaken, Adele Schwartz
Drummer, Heidi E.
Hellard, Margaret E.
Funding for this research was provided by:
National Health and Medical Research Council (APP1132902)
Article History
Received: 15 April 2019
Accepted: 19 August 2019
First Online: 18 September 2019
Ethics approval and consent to participate
: Not applicable
: Not applicable
: NS receives investigator-initiated research funding from Gilead Sciences unrelated to this work. AT is an advisory board member for Gilead Sciences, AbbVie, BMS, Merck, and Roche Diagnostics and a speaker for Gilead, Merck, BMS, AbbVie, and Roche Diagnostics. EB is developing vaccines as part of an Fp7 EU consortium (PEACHI) that includes GSK as a partner and has received funding to her institution from GSK to deliver studies in hepatitis C vaccines that encode class II invariant chain. MH and the Burnet Institute receive investigator-initiated research funding from Gilead Sciences, AbbVie, and BMS.